Phase IIa Safety and Efficacy Study of SPP635 in Mild to Moderate Hypertension
This study is conducted to investigate the effect of the oral renin inhibitor SPP635 on blood pressure in patients with mild to moderate hypertension.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
|Official Title:||A Phase IIa, Double-Blind, Placebo-Controlled, Randomised, Parallel-Design, Four-Week Study to Investigate the Safety and Efficacy of the Oral Renin Inhibitor SPP635 Once Daily in Patients With Mild to Moderate Hypertension|
- Lowering of systolic office blood pressure [ Time Frame: four weeks ]
- Lowering of diastolic office blood pressure [ Time Frame: four weeks ]
- Lowering of systolic and diastolic blood pressure (ABPM) [ Time Frame: four weeks ]
|Study Start Date:||October 2006|
|Study Completion Date:||May 2007|
Renin-Angiotensin system blockade is a well established target for treatment of high blood pressure. Blocking the system at the initial step, however, is a rather new concept that could only be implemented very recently through the availability of novel, oral, renin inhibitors. This study investigates the safety and efficacy of a novel oral renin inhibitor, SPP635.